48:
254:
439:
57:
251:
41:
482:
561:
220:
456:
192:
444:
82:
266:
94:
189:
134:
110:
309:
113:
486:
379:
354:
334:
324:
286:
450:
410:
223:
17:
555:
496:
124:
364:
349:
294:
70:
61:
425:
384:
369:
359:
262:
164:
154:
129:
400:
374:
329:
319:
304:
231:
210:
205:
200:
179:
174:
169:
100:
26:
339:
314:
299:
272:
241:
236:
159:
144:
419:
415:
405:
344:
139:
79:
524:
will show the template collapsed, i.e. hidden apart from its title bar.
489:), it is hidden apart from its title bar; if not, it is fully visible.
90:
481:, meaning that if there is another collapsible item on the page (a
30:
548:
will show the template expanded, i.e. fully visible.
527:
503:
393:
285:
250:
219:
188:
109:
78:
69:
492:To change this template's initial visibility, the
42:
8:
75:
49:
35:
27:
476:initial visibility currently defaults to
493:
7:
487:table with the collapsible attribute
25:
1:
578:
434:
18:Template:Antiparkinson
562:Drug templates by ATC
532:Antiparkinson agents
508:Antiparkinson agents
58:Antiparkinson agents
135:Dihydroergocryptine
461:Never to phase III
471:
470:
281:
280:
16:(Redirected from
569:
547:
546:
542:
539:
536:
533:
530:
523:
522:
518:
515:
512:
509:
506:
495:
494:|state=
479:
474:This template's
310:Chlorphenoxamine
287:Anticholinergics
76:
51:
44:
37:
28:
21:
577:
576:
572:
571:
570:
568:
567:
566:
552:
551:
544:
540:
537:
534:
531:
528:
520:
516:
513:
510:
507:
504:
483:navbox, sidebar
477:
472:
467:
466:
451:Clinical trials
430:
416:Methylxanthines
389:
380:Trihexyphenidyl
355:Phenglutarimide
335:Etybenzatropine
325:Diphenhydramine
277:
246:
215:
184:
105:
65:
55:
23:
22:
15:
12:
11:
5:
575:
573:
565:
564:
554:
553:
550:
549:
525:
469:
468:
465:
464:
463:
462:
459:
448:
442:
436:
435:
432:
431:
429:
428:
423:
413:
411:Istradefylline
408:
403:
397:
395:
391:
390:
388:
387:
382:
377:
372:
367:
362:
357:
352:
347:
342:
337:
332:
327:
322:
317:
312:
307:
302:
297:
291:
289:
283:
282:
279:
278:
276:
275:
270:
259:
257:
248:
247:
245:
244:
239:
234:
228:
226:
217:
216:
214:
213:
208:
203:
197:
195:
186:
185:
183:
182:
177:
172:
167:
162:
157:
148:
147:
142:
137:
132:
127:
118:
116:
107:
106:
104:
103:
98:
87:
85:
73:
67:
66:
56:
54:
53:
46:
39:
31:
24:
14:
13:
10:
9:
6:
4:
3:
2:
574:
563:
560:
559:
557:
526:
502:
501:
500:
499:may be used:
498:
490:
488:
484:
480:
460:
458:
455:
454:
452:
449:
446:
443:
441:
438:
437:
433:
427:
424:
421:
417:
414:
412:
409:
407:
404:
402:
399:
398:
396:
392:
386:
383:
381:
378:
376:
373:
371:
368:
366:
363:
361:
358:
356:
353:
351:
348:
346:
343:
341:
338:
336:
333:
331:
328:
326:
323:
321:
318:
316:
313:
311:
308:
306:
303:
301:
298:
296:
293:
292:
290:
288:
284:
274:
271:
268:
264:
261:
260:
258:
256:
253:
249:
243:
240:
238:
235:
233:
230:
229:
227:
225:
222:
218:
212:
209:
207:
204:
202:
199:
198:
196:
194:
191:
187:
181:
178:
176:
173:
171:
168:
166:
163:
161:
158:
156:
153:
152:Non-ergoline:
150:
149:
146:
143:
141:
138:
136:
133:
131:
128:
126:
125:Bromocriptine
123:
120:
119:
117:
115:
112:
108:
102:
99:
96:
92:
89:
88:
86:
84:
81:
77:
74:
72:
71:Dopaminergics
68:
63:
59:
52:
47:
45:
40:
38:
33:
32:
29:
19:
491:
478:autocollapse
475:
473:
365:Procyclidine
350:Orphenadrine
295:Benzatropine
151:
121:
95:+benserazide
34:
447:from market
426:Rimantadine
385:Tropatepine
370:Profenamine
360:Piroheptine
263:Benserazide
165:Pramipexole
155:Apomorphine
130:Cabergoline
111:DA receptor
401:Amantadine
375:Tigloidine
330:Etanautine
320:Dexetimide
305:Bornaprine
255:inhibitors
232:Entacapone
224:inhibitors
211:Selegiline
206:Safinamide
201:Rasagiline
193:inhibitors
180:Talipexole
175:Rotigotine
170:Ropinirole
101:Melevodopa
83:precursors
519:collapsed
497:parameter
457:Phase III
445:Withdrawn
340:Mazaticol
315:Cycrimine
300:Biperiden
273:Carbidopa
267:+levodopa
242:Tolcapone
237:Opicapone
160:Piribedil
145:Pergolide
122:Ergoline:
556:Category
543:expanded
420:caffeine
406:Budipine
345:Metixene
140:Lisuride
114:agonists
91:Levodopa
418:(e.g.,
440:WHO-EM
394:Others
538:state
514:state
485:, or
190:MAO-B
252:AAAD
221:COMT
62:N04
558::
545:}}
529:{{
521:}}
505:{{
453::
80:DA
541:=
535:|
517:=
511:|
422:)
269:)
265:(
97:)
93:(
64:)
60:(
50:e
43:t
36:v
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.